IL139682A0 - Cabergoline and pramipexole for treating cns diseases especially parkinson's disease - Google Patents

Cabergoline and pramipexole for treating cns diseases especially parkinson's disease

Info

Publication number
IL139682A0
IL139682A0 IL13968299A IL13968299A IL139682A0 IL 139682 A0 IL139682 A0 IL 139682A0 IL 13968299 A IL13968299 A IL 13968299A IL 13968299 A IL13968299 A IL 13968299A IL 139682 A0 IL139682 A0 IL 139682A0
Authority
IL
Israel
Prior art keywords
cabergoline
pramipexole
disease
cns diseases
treating cns
Prior art date
Application number
IL13968299A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL139682A0 publication Critical patent/IL139682A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL13968299A 1998-05-15 1999-05-07 Cabergoline and pramipexole for treating cns diseases especially parkinson's disease IL139682A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8561998P 1998-05-15 1998-05-15
US8794398P 1998-06-04 1998-06-04
PCT/US1999/007024 WO1999059563A2 (en) 1998-05-15 1999-05-07 Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease

Publications (1)

Publication Number Publication Date
IL139682A0 true IL139682A0 (en) 2002-02-10

Family

ID=26772918

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13968299A IL139682A0 (en) 1998-05-15 1999-05-07 Cabergoline and pramipexole for treating cns diseases especially parkinson's disease

Country Status (22)

Country Link
US (1) US6503920B1 (de)
EP (1) EP1076559B1 (de)
JP (1) JP2002515425A (de)
KR (3) KR20010043612A (de)
CN (1) CN1301159A (de)
AT (1) ATE310517T1 (de)
AU (1) AU748629B2 (de)
BR (1) BR9909917A (de)
CA (1) CA2327299A1 (de)
DE (1) DE69928521T2 (de)
DK (1) DK1076559T3 (de)
EA (4) EA200300125A1 (de)
ES (1) ES2251191T3 (de)
HU (1) HUP0101803A3 (de)
IL (1) IL139682A0 (de)
NO (1) NO20005757L (de)
NZ (2) NZ508184A (de)
PL (1) PL344574A1 (de)
SG (1) SG121745A1 (de)
SK (1) SK16272000A3 (de)
TR (1) TR200003356T2 (de)
WO (1) WO1999059563A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
AR040682A1 (es) 2002-07-25 2005-04-13 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
GB0221513D0 (en) * 2002-09-17 2002-10-23 Generics Uk Ltd Novel compounds and processes
CA2576386A1 (en) 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CN101005831B (zh) 2004-08-13 2010-11-10 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂
EP1988875A2 (de) * 2006-02-10 2008-11-12 Boehringer Ingelheim International GmbH Modifizierte freisetzungsformulierung
PL232974B1 (pl) * 2015-12-09 2019-08-30 Ofta Spolka Z Ograniczona Odpowiedzialnoscia Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
WO1995005176A1 (en) * 1993-08-18 1995-02-23 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
FR2728374A1 (fr) * 1994-12-15 1996-06-21 Aerospatiale Procede et dispositif pour fournir une information, alerte ou alarme pour un aeronef a proximite du sol
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent

Also Published As

Publication number Publication date
AU3741999A (en) 1999-12-06
KR20060056417A (ko) 2006-05-24
EP1076559B1 (de) 2005-11-23
WO1999059563A2 (en) 1999-11-25
TR200003356T2 (tr) 2001-03-21
KR20060056416A (ko) 2006-05-24
NZ526071A (en) 2004-11-26
US6503920B1 (en) 2003-01-07
HUP0101803A3 (en) 2002-10-28
EP1076559A2 (de) 2001-02-21
DE69928521D1 (de) 2005-12-29
EA200300124A1 (ru) 2003-10-30
ES2251191T3 (es) 2006-04-16
AU748629B2 (en) 2002-06-06
EA200200955A1 (ru) 2002-12-26
HUP0101803A2 (hu) 2002-03-28
EA200001192A1 (ru) 2001-04-23
WO1999059563A3 (en) 2000-04-13
NO20005757D0 (no) 2000-11-14
PL344574A1 (en) 2001-11-05
SK16272000A3 (sk) 2001-05-10
ATE310517T1 (de) 2005-12-15
BR9909917A (pt) 2000-12-26
JP2002515425A (ja) 2002-05-28
DK1076559T3 (da) 2006-01-16
DE69928521T2 (de) 2006-07-27
NO20005757L (no) 2000-11-14
EA004474B1 (ru) 2004-04-29
NZ508184A (en) 2004-01-30
KR20010043612A (ko) 2001-05-25
SG121745A1 (en) 2006-05-26
EA200300125A1 (ru) 2003-06-26
CN1301159A (zh) 2001-06-27
CA2327299A1 (en) 1999-11-25

Similar Documents

Publication Publication Date Title
BE2018C038I2 (de)
TW200509968A (en) Prevention and treatment of synucleinopathic disease
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
IL139682A0 (en) Cabergoline and pramipexole for treating cns diseases especially parkinson's disease
HK1006421A1 (en) Levobupivacaine useful for managing chronic pain
PL309596A1 (en) Application of anticonvulsant agents in treating parkinson disease and parkinsonian syndromes
IL157413A0 (en) Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
FR2777781B1 (fr) Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
NZ504419A (en) The use of carvedilol for treating amyloid diseases such as Alzheimer's
HK1020867A1 (en) The topical use of kappa opioid agonists to treat ocular pain k
GB0020504D0 (en) Therapeutic method
MXPA03006843A (es) Derivados heterociclicos novedosos de ureas y su uso como ligandos para receptor d3 de dopamina.
MY124071A (en) Treatment of viral disease in swine
HK1047695A1 (en) Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
GR3033061T3 (en) Use of benzonaphthalene derivatives to make medicaments for treating diseases of the central nervous system
NZ328915A (en) use of sulbutiamine to treat psychomotor and psychointellectual disorders
NZ268914A (en) Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease
PT1304107E (pt) Utilizacao de derivados de oxazolidininas para o tratamento da psoriase
MX9503363A (es) N-(2,6-dioxo-3-piperidil) ftalimida (generico talidomida como tratamiento del sindrome de desgaste asociado con la infeccion por vih-1.
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
UA36664A (uk) Спосіб лікування хронічного гломерулонефриту
ZA200107138B (en) Use of fluorinated triazoles for treating pain and affective or attention disorders.